Alcon Completes Acquisition of Aerie Pharmaceuticals - Eyewire+
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Aerie Pharmaceuticals, Inc.
Aerie launches Ph3 trial for Roclatan eye drug in Europe - Drug Delivery Business
EX-99.1
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union | Business Wire
Aerie to build manufacturing facility in Ireland
Aerie Pharmaceuticals
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire
Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal
Santen Expands License Agreement with Aerie for Rhopressa and Rocklatan | Market Scope
Articles about Aerie Pharmaceuticals, Inc. | page 4
Mitchell de Long on LinkedIn: Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer |…
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Rhopressa enrolled in second Phase 3 registration trial
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
Aerie Pharmaceuticals, Inc. (Aerie Pharmace) Stock Price & News | AERI
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC
Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management | Ophthalmology Innovation Source
Alcon to buy Aerie Pharmaceuticals for $770M - News - MM+M
